Reading WGS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track WGS free→Reading WGS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track WGS free→QuarterlyIQ Insights · WGS
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 16, 2026, GeneDx Holdings Corp. (the “Company”) announced the appointment of Mark Gardner, age 60, in the role of President, which was effective on June 15, 2026. As President, Mr. Gardner will oversee the Company’s lab and commercial operations. Mr. Gardner will report to Katherine Stueland, Chief Executive Officer of the Company, and will…
Results of Operations and Financial Condition. Financial Results for the Quarter Ended March 31, 2026 On May 4, 2026 , GeneDx Holdings Corp. (the “Company”) issued a press release (the “Press Release”) and will hold a conference call announcing the Company's financial results for the quarter ended March 31, 2026 . Copies of the Press Release and Earnings Presentation are furnished as Exhibits 99.1 and 99.3, respectively, to this Current Report on Form 8-K. Consolidated Statements of Operation…
Termination of a Material Definitive Agreement. The information provided in
Entry Into a Material Definitive Agreement. Loan Agreement On February 27, 2026 (the “Closing Date”), GeneDx Holdings Corp. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”), with Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C. (collectively, the “Blackstone Representative” and referred to herein as “Blackstone”), certain subsidiaries of the Company party thereto as Guarantors, Wilmington Trust, National Association, as Agent and the l…
Cautionary Statement Regarding Forward-Looking Statements This Report contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the Loan Agreement and the transactions contemplated thereby, and the use of proceeds of the Term Loan. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “shoul…
Results of Operations and Financial Condition. On February 23, 2026 , GeneDx Holdings Corp. (the “Company”) issued a press release (the “Press Release”) and will hold a conference call announcing the Company's financial results for the year ended December 31, 2025 . Copies of the Press Release and Earnings Presentation are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K. The information furnished with this Item 2.02, including Exhibits 99.1 and 99.2 heret…
Results of Operations and Financial Condition. The information set forth in
Results of Operations and Financial Condition. On October 28, 2025 , GeneDx Holdings Corp. (the “Company”) issued a press release (the “Press Release”) and will hold a conference call announcing the Company's financial results for the quarter ended September 30, 2025 . Copies of the Press Release and Earnings Presentation are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K. The information furnished with this Item 2.02, including Exhibits 99.1 and 99.2 he…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 17, 2025, the Board of Directors (the “Board”) of GeneDx Holdings Corp., a Delaware corporation (the “Company”), appointed Thomas Fuchs, Dr.sc., effective immediately, as a Class I director on the Board with a term expiring at the Company’s 2028 Annual Meeting of Stockholders. In connection with Dr. Fuchs’s appointment to the Board, th…
Results of Operations and Financial Condition. On July 29, 2025 , GeneDx Holdings Corp. (the “Company”) issued a press release (the “Press Release”) and will hold a conference call announcing the Company's financial results for the quarter ended June 30, 2025 . Copies of the Press Release and Earnings Presentation are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K. The information furnished with this Item 2.02, including Exhibits 99.1 and 99.2 hereto, sh…
Results of Operations and Financial Condition. On April 30, 2025 , GeneDx Holdings Corp. (the “Company”) issued a press release (the “Press Release”) and will hold a conference call announcing the Company's financial results for the quarter ended March 31, 2025 . Copies of the Press Release and Earnings Presentation are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K. The information furnished with this Item 2.02, including Exhibits 99.1 and 99.2 hereto,…
Entry into a Material Definitive Agreement On April 15, 2025, GeneDx Holdings Corp., a Delaware corporation (the “Company,” “we,” “us” and “our”), entered into an Agreement and Plan of Merger, dated as of April 15, 2025 (the “Merger Agreement”), by and among the Company, Project Flare Merger Sub, Inc., a Delaware corporation (“Merger Sub”) and a wholly-owned subsidiary of the Company, Fabric Genomics, Inc., a Delaware corporation (“Fabric Genomics”), and Martin Reese, as the Agent, pursuant t…
Unregistered Sale of Equity Securities The information contained in
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.